A multicenter study of the safety of intravenous iron dextran (IVFe) in hemodialysis patients

Clinical Applications of Iron Management in Peritoneal Dialysis Patients

“…Hamstra et al (46) found that serious immediate reactions occurred in some 0.6% of IV iron dextran infusions. This was verified in a large retrospective study involving four centers and 573 HD patients treated with IV iron dextran over a 2-year period (49). The incidence of severe reactions was found to be 0.7% in this study (49).…”

“…This was verified in a large retrospective study involving four centers and 573 HD patients treated with IV iron dextran over a 2‐year period ( 49). The incidence of severe reactions was found to be 0.7% in this study ( 49). The administration of a 25‐mg test dose is mandatory and can be followed by the IV bolus infusion if the patient remains stable after 30 min of monitoring.…”

Current Issues in Iron Management in End-Stage Renal Disease

“…In a study of 481 nonuremic patients, Hamstra et al (27) found the risk of serious immediate reactions to be approximately 0.6%. We recently completed a retrospective, four center study involving 573 hemodialysis patients treated over a two year period (28). Dyspnea and itching were the most common symptoms noted.…”

Current Issues in Iron Management in End‐Stage Renal Disease

“…(27) found the risk ofserious immediate reactionsto be approximately 0.6%. We recently completed a retrospective, fourcenter study involving 573 hemodialysis patients treated over a two year period(28). Dyspnea and itchingwere the most common symptoms noted.…”